What's in ILiAD Biotechnologies's pipeline?

ILiAD Biotechnologies has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with ILiAD Biotechnologies's portfolio?

Top competitors by shared drug class: Aduro Biotech, Inc., Aeras, Aga Khan University, Aimei Vacin BioPharm (Zhejiang) Co., Ltd., Alba Maria Ropero.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/iliad-biotechnologies.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

ILiAD Biotechnologies — Portfolio Competitive Intelligence Brief

ILiAD Biotechnologies pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Aduro Biotech, Inc. · 1 shared drug class
Aeras · 1 shared drug class
Aga Khan University · 1 shared drug class
Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
Alba Maria Ropero · 1 shared drug class
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ILiAD Biotechnologies:

Cite this brief

Drug Landscape (2026). ILiAD Biotechnologies — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/iliad-biotechnologies. Accessed 2026-05-16.